Pharma Works – Tenil Fri, 11 Jun 2021 21:29:56 +0000 en-US hourly 1 Pharma Works – Tenil 32 32 Unvaccinated adults are more likely to be uninsured, study finds Fri, 11 Jun 2021 20:31:43 +0000

American adults who have not yet been vaccinated against Covid-19 are more likely to be uninsured and have lower incomes, according to a Kaiser Family Foundation report released on Friday.

Among people under 65, those without insurance represent 24% of the unvaccinated population, while only 12% of those insured have not received the vaccine, according to the report. About two-fifths of all unvaccinated adults (42%) report earning less than $ 40,000 per year.

The data shows that while the federal government is making efforts to improve access to the Covid-19 vaccine for uninsured people, these people may still be difficult to reach or not understand how the United States is deploying vaccines. Even though the vaccines are free for everyone, a third of those polled who say they take a “wait and see” approach to the vaccine also say they are worried about having to pay for it.

The Health Resources and Services Administration is helping people without insurance access Covid-19 treatment and vaccinations through its uninsured COVID-19 program, which reimburses providers at national Medicare rates for services.

Many states, public health departments, and employers across the country are offering incentives to make those who are reluctant more eager to be vaccinated.

Incentives might work

The report found that 46% of those who want to ‘wait and see’ how the vaccine works for others said they would be more likely to get the vaccine if it was offered in a place they normally go to for a while. to be treated. In this same group, about two-fifths said they would be more likely to get stung if it was necessary to fly on an airplane (41%) or attend large gatherings (40%).

Many adults in the “wait and see group” and those who have said they “definitely will not” get vaccinated are concerned about the safety of the vaccine, according to the report. Concerns differ from group to group and range from the impact of the vaccine on fertility to (unfounded) worries about having to pay for the vaccine and getting the vaccine in a place of trust.

The main demographic differences between these two groups focus on racial and ethnic identity, according to the report.

Half of the people in the “wait and see” group are people of color. Throughout the deployment, black and Hispanic adults said they would “wait for him to be available for a while to see how it worked for others,” the KFF revealed.

Adults who say they will “definitely not” get a Covid vaccine are “overwhelmingly” white – 70% versus 49% of the “wait and see” group, according to the report.

Black and Hispanic adults lag behind in immunization rates in part because of difficulty accessing immunization locations and services. But the current awareness is aimed at bridging the gap, the KFF said.

Source link

]]> 0
Creso Pharma secures direct access to the world’s largest cannabis market with successful dual listing in the United States Thu, 10 Jun 2021 23:55:30 +0000

Listing will provide Creso Pharma with access not only to deeper capital markets, but also to the rapidly growing North American cannabis industry.

The long-awaited dual listing of Creso Pharma (ASX: CPH) shares in the US has finally taken place, with the share expected to start trading on the OTCQB market from June 11.

The listing plan has been in the works for some time and is expected to unlock significant shareholder value and provide Creso with access to the world’s largest capital market.

The move was made in the wake of growing interest from North American investors, after the company saw strong sales growth from its wholly owned subsidiary Mernova and named Bruce Linton as one of the top cannabis entrepreneurs. , as a strategic advisor.

North American investors have also sought exposure to Creso after seeing significant progress made by its US acquisition target, Halucenex.

The dual listing will provide Creso with access to deeper capital markets, allowing its institutional and retail investors in North America to invest directly in an established cannabis and psychedelic drug business.

“The company’s dual listing coincides with the growth Creso Pharma has recently achieved in the United States and North America in general,” commented Adam Blumenthal, CEO of Creso Pharma.

“Recently, we have focused on building a very strong base in the region, which is underpinned by the expansion of operations and key appointments that will provide a number of value catalysts for Australian and North American investors. Americans. “

The dual listing will also provide greater visibility for clinical studies at universities, hospitals and research centers as Creso prepares to enter the lucrative psychedelic market.

Creso Pharma will trade under code COPHF.

Legislative rear winds

The entry into the US market aligns directly with Creso’s strategic perspective to expand its operations in the region.

It will also give the company the opportunity for a potential reassessment, as it offers analysts and investors an easier comparison with its US and Canadian peers operating in the cannabis and psychedelic drug industries.

The recent strong demand for cannabis in the region follows significant cannabis legislative changes in the United States.
The Marijuana Opportunity Reinvestment and Expungement (MORE) Act, for example, was recently reintroduced in Congress by US federal lawmakers, which would remove the federal cannabis ban.

The company is also gearing up to enter the California market, following the state’s passage of Senate Bill 519, which would legalize the use and possession of psilocybin and other psychedelic compounds.

If passed, SB 519 will approve the use of mushrooms, MDMA, LSD, mescaline and ibogaine for those eligible.

These recent developments have provided Creso and Halucenex with a major market opportunity in California and the United States.

The company intends to capitalize on these opportunities and has entered into discussions to advance partnerships and market entry strategies.

“The cannabis and psychedelic medicine sectors continue to gain traction,” the company said.
“Recent regulatory changes have left Creso in a favorable position, and it is well positioned to become a world leader in both sectors,” added Blumenthal.

Creso is also currently taking steps to gain approval from the Depository Trust Company (DTC), which would allow real-time electronic clearing and settlement in the United States for its common stock.

This decision will allow access to trading with major online brokers such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and E-trade, all of which offer trading services in the OTCQB market.

This article was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publication.

This article is not advice on financial products. You should consider getting independent advice before making any financial decisions.

You might be interested in

Source link

]]> 0
Tenax Therapeutics to join the Russell Microcap® Index Thu, 10 Jun 2021 12:30:00 +0000

MORRISVILLE, NC – (COMMERCIAL THREAD) – Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that treat cardiovascular and pulmonary disease with high unmet medical need, is expected to join the Russell Microcap® Index at the conclusion of the Russell 2021 Indexes’ annual replenishment effect after the U.S. market opens on June 28, according to a preliminary list of additions released on June 4.

Russell Microcap Membership® The index, which remains in place for one year, signifies automatic inclusion in the appropriate growth and value style indices. FTSE Russell determines membership in its Russell Indices primarily through objective market capitalization rankings and style attributes.

“Our inclusion in the Russell Microcap Index comes at an exciting time for our company, as we plan to advance our two flagship drug development programs (imatinib and levosimendan) into Phase 3 clinical trials,” said Anthony DiTonno, CEO of Tenax Therapeutics. “Over the next few months, we also anticipate a series of important research publications that will support Tenax’s pioneering approach to the treatment of pulmonary hypertension and heart failure with preserved ejection fraction. We therefore appreciate our inclusion in this widely followed index, which should increase our visibility with institutional investors at such an important time in our company’s growth.

Russell Indices are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. About $ 10.6 trillion in assets is compared to Russell’s U.S. indices. The Russell Indices are part of FTSE Russell, one of the world’s leading index providers. For more information on the Russell Microcap® Index and the Russell Reconstitution, see the “Russell Reconstruction” section on the FTSE Russell website.

About FTSE Russell

FTSE Russell is a global index leader providing innovative benchmarking, analytics and data solutions to investors around the world. FTSE Russell calculates thousands of indices that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the global investment market.

The expertise and products of the FTSE Russell Index are widely used by institutional and retail investors around the world. About $ 17.9 trillion is currently compared to the FTSE Russell indices. For more than 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen the FTSE Russell Indices to benchmark their investment performance and create ETFs, structured products and index derivatives.

A set of basic universal principles guide the design and management of the FTSE Russell Index: a transparent rules-based methodology is informed by committees independent of major market players. FTSE Russell is focused on applying the highest industry standards in index design and governance and adheres to the principles of IOSCO. FTSE Russell is also focused on index innovation and client partnerships with the aim of improving the breadth, depth and reach of its offering.

FTSE Russell is 100% owned by the London Stock Exchange Group. For more information visit

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products that treat cardiovascular and pulmonary disease with high unmet medical need. The Company has a world-class scientific advisory team comprising recognized global experts in pulmonary hypertension. The Company owns the North American rights to develop and commercialize levosimendan and recently published the detailed results of the phase 2 HELP study of levosimendan in pulmonary hypertension associated with heart failure and preserved ejection fraction. (PH-HFpEF) at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting. Tenax is also developing a delayed-release oral formulation of imatinib, designed to prevent gastric irritation, in a single pivotal trial according to route 505 (b) (2). For more information, visit

About Lévosimendan

Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action. It was originally developed for intravenous use in hospitalized patients with acute decompensated heart failure. It was discovered and developed by Orion Pharma, Orion Corporation of Espoo Finland, and is currently approved in over 60 countries for this indication and is not available in the United States. Tenax Therapeutics acquired the North American rights to develop and commercialize levosimendan from Phyxius Pharma, Inc.

About imatinib

Imatinib is an antiproliferative agent developed to target BCR-ABL tyrosine kinase in patients with chronic myelogenous leukemia. The inhibitory effects of imatinib on the PDGF and c-KIT receptors suggest that it may be effective in PAH. Imatinib reversed experimentally induced pulmonary hypertension and has pulmonary vasodilator effects in animal models and pro-apoptotic effects on pulmonary artery smooth muscle cells of patients with idiopathic PAH. In a phase 3 clinical trial, imatinib produced significant improvements in exercise capacity, but a high dropout rate attributed largely to gastric intolerance precluded regulatory approval.

Caution Regarding Forward-Looking Statements

This press release contains certain forward-looking statements of the Company which involve risks and uncertainties and reflect the judgment of the Company as of the date of this press release. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, matters beyond the control of the Company which could cause delays in the clinical study, the launch of new products and customer acceptance of these new products; matters beyond the control of the Company that could affect the Company’s continued compliance with Nasdaq listing requirements; the impact of management changes on the Company’s business and unanticipated unanticipated charges, costs and expenses that may arise as a result of management changes; and other risks and uncertainties as described in documents filed by the Company with the Securities and Exchange Commission, including in its annual report on Form 10-K filed on March 31, 2021 and its quarterly report on Form 10 -Q filed on May 17, 2021, along with its other documents filed with the SEC. The Company disclaims any intention or obligation to update these forward-looking statements beyond the date of this press release. Statements in this press release regarding management’s future expectations, beliefs, objectives, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Source link

]]> 0
Stop Blaming Pharmac – We’d Be Worse Without It Wed, 09 Jun 2021 17:00:00 +0000

NOTICE: Penny Tucker worries that there are “miracle drugs and biologics that have turned many conditions from a death sentence into a surmountable challenge” and blames Pharmac for the lack of supply of these. She is disappointed that Pharmac’s budget is not part of the review and criticizes its bureaucracy.

I admit that she has not declared any involvement in the pharmaceutical industry, but her arguments are much the same as those of Graeme Jarvis of Medicines New Zealand. It makes no mention of the role that the pharmaceutical industry plays in the difficulty of financing them.

The title “Pharmac works well. Unless you are sick ”is seriously misleading. The opposite is true for the vast majority of New Zealanders, who received pharmaceuticals worth $ 1.04 billion last year.

“We need to prioritize our spending to get the best result for the most people,” writes Ben Gray.  “It's Pharmac's job with the pharmaceutical budget.


“We need to prioritize our spending to get the best result for the most people,” writes Ben Gray. “It’s Pharmac’s job with the pharmaceutical budget. “

Of course, some people have missed new treatments. This is true for all aspects of the health system; people miss GP care, emergency care, outpatient appointments and elective surgery because we can’t provide everything everyone wants. We must prioritize our spending to get the best result for the greatest number. This is Pharmac’s job with the pharmaceutical budget.

* Pharmac does a great job, but loses the PR battle hands down
* Pharmac works well. Unless you are sick
* Pharmac magazine misses a political elephant in the room

It is wrong to blame Pharmac for its budget. It does not set its own budget; which is set by the government. The government faces many competing interests in how to spend our money to improve health. Personally, I would be in favor of increasing nurses’ salaries, ensuring a reliable supply of clean water and sewage disposal, and allowing the poorest in our community to have stable housing. We know that spending on public health priorities has a much bigger effect on health than most therapeutic products (the obvious exception being the Covid-19 vaccine).

Health Minister Andrew Little and Prime Minister Jacinda Ardern announced a review of the drug buying agency Pharmac in March.


Health Minister Andrew Little and Prime Minister Jacinda Ardern announced a review of the drug buying agency Pharmac in March.

I would be horrified if we got rid of the Pharmac bureaucracy. The United States has a much lighter drug bureaucracy. The most striking example is that of the more than 400,000 people who have died as a result of the fraudulent marketing of Oxycontin by Purdue Pharma. They demanded evidence that did not exist to say that it was not addicting. They spent eight times as much as the gun lobby to influence politicians (US $ 880 million in nine years); they have manipulated all levels of the system.

American doctors still prescribe 100 times more opioid drugs than New Zealand doctors because of this influence. New Zealand fortunately had a “bureaucracy” that demanded adequate evidence for any claims, noted that it was little different from other (cheaper) opiates, and provided information to doctors to resist prescribing pressures.

The other extreme example is Tamiflu, which was purchased in large quantities by governments around the world during the H1N1 flu epidemic. Roche has been warned against false advertising. He claimed the drug was able to prevent hospitalizations and the side effects of the flu, but had no supporting evidence and was warned by the US Federal Drug Administration. Strange that a drug that brought in billions of dollars at the time is no longer used in a meaningful way. It was not the magic cure that was being touted.

There is a long list of legal settlements amounting to billions of dollars as a result of fraudulent behavior by pharmaceutical companies. The industry has proven to be untrustworthy and interested primarily in the bottom line. Pharmac has been successful in controlling some of the worst behaviors in New Zealand and limiting price increases.

Ben Gray: “There is no doubt that there are many new drugs out there, and some of them are very effective for particular conditions.  We cannot all afford this and we may wish to spend our money on other priorities.

Jim Chipp / Stuff

Ben Gray: “There is no doubt that there are many new drugs out there, and some of them are very effective for particular conditions. We cannot all afford this and we may wish to spend our money on other priorities. “(File photo)

It’s a difficult job to assess the evidence for a drug’s effectiveness and harm, especially when studies funded by industry have significantly more positive results than studies by independent researchers. There are well-documented issues of publication bias (where only positive studies are published and negative studies are hidden).

Evaluating the cost / benefit of a drug is even more difficult, and yet it must be done because it is the only way to make reasonable choices about what we will fund and what we will not. If we could trust the information that companies provide, it might be an easier job, but their past behavior means we can’t.

Tucker’s spending analysis is simplistic. Pharmac’s annual report details expenses; it is not hidden. International comparisons are problematic. What is important is not the total budget, but the value of the treatment purchased. In most markets, there is a much higher proportion of brand-name drugs purchased than generics, which dramatically increases the bill without changing the level of care.

Pharmac is realizing significant savings through its benchmarking and negotiation pricing processes, totaling $ 74 million last year. Spending in other countries does not cover the entire population with large user fees (for example, in the United States for people without insurance). The fact that we spend less than other countries does not give any information on the efficiency with which this money is spent.

There is no doubt that there are many new drugs out there, and some of them are very effective for particular conditions. We cannot all afford this, and we may wish to spend our money on other priorities. Pharmac is only one player in this field. The government sets the budget and the pharmaceutical industry benefits from it. All three actors must be taken into account in discussions on access to pharmaceuticals.

* Ben Gray, former general practitioner, is associate professor at Department of Primary Health Care and General Medicine at the University of Otago, Wellington.

Source link

]]> 0
Bioneemtec India is working on technology to synthesize chemical used in Covid-19 vaccination – The New Indian Express Wed, 09 Jun 2021 00:28:00 +0000

Express news service

CHENNAI: As India scrambles to find key raw materials to make vaccines and medicines during the pandemic, a Chennai-based start-up is developing technology for the synthesis of one of the chemicals used in the Covid-19 vaccine preparation.

Dr Menaga Magendran, Managing Director of Bioneemtec India, told Express that the company has filed a patent for the “Process for the Synthesis of Chiral Molecules Derived from Quinoline and Rhein effective against Covid-19”.
“The recent outbreak of Covid-19 belonging to the SARS family has been analyzed for its activity and structure. From its 3D structure and the path of infection, scientists have found that antimalarial compounds like hydroxychloroquine and anti-HIV compounds like Remdesivir are active in controlling Covid-19. The present invention provides a method of synthesizing active chiral compounds derived from quinolone and rhein with controlling activity against Covid-19, ”said Dr. Menaga.

“That aside, we have identified a chemical used as a virus deactivator in the preparation of vaccines, which appears to be imported from abroad. Our experts are working on the synthesis of this chemical using a continuous flow chemical reactor, ”she added.

India imports 80 percent of key raw materials from China. The Menaga company located in Siruseri is one of the few companies in the country working on ways to synthesize key raw materials using green chemistry methodology.

The company’s success lies in the use of the Continuous Flow Chemistry Reactor, where they develop key starting materials and identify new pathways for API synthesis using green chemistry in which they also support customers. international pharmaceuticals.

Having expertise in China, Menaga and her husband Magendran, who returned to India after working six to seven years in China, want India to be self-sufficient in terms of the start or essential raw materials for drugs. Pharmaceutical platforms generally have four different phases.

These include key raw materials, intermediates (chemical compounds that form the building blocks of the active pharmaceutical ingredient), active pharmaceutical ingredient (API); and finally formulations, the process in which different chemicals, including the active drug, are combined to produce a final drug.

J Jayaseelan, managing director of Saimirra Innopharm Limited and chairman of the Indian Association of Drug Manufacturers, said the key starting material is thriving in China with government support.

Source link

]]> 0
The app analyzes recreational drugs to inform users about dangers and side effects Tue, 08 Jun 2021 09:40:06 +0000

An app has been launched to reduce the harm from recreational drugs by allowing users to identify which pill they are taking and understand the risks that come with it.

Pill-iD was developed by British creative technology agency Rehab and French advertising agency Herezie. With the end of Covid-19 lockdown restrictions and the potential reopening of clubs and festivals, companies have said the need to reduce the harm from drugs is urgent.

Pill-iD is currently only a working prototype, but Rehab and Herezie aim to release it by winter 2021. It works by asking users to take a photo of a pill using the camera’s camera. their phone (they can also use an existing image), which is then scanned using a machine-learning technology through a European drug database, before showing the user a match. If possible, the database will identify the pill, its likely dosage, level of risk, and expected side effects.

The app is not designed to encourage drug use, but is there to educate recreational drug users about the known risks of the pills they take. The goal of the project is to recognize the widespread use of recreational drugs such as MDMA and to reduce the harm.

Data from the Office of National Statistics (ONS) on drug use in England and Wales ending March 2020 showed that around 1.1 million people had taken a Class A drug in the past the last year. Levels of drug use increased when people frequented nightclubs. ONS data showed that 42.5% of people who had visited a nightclub at least four times in a month reported using drugs in the past year. This was compared to 7.5% of users who had not visited a nightclub in the past month.

Rob Bennett, CEO of Rehab, commented: “The problem of recreational drugs and the need to reduce harm is a critical health issue across Europe, and we are proud to have developed this app together with Herezie. The subject is undoubtedly taboo for some, but our Hack Weeks all aim to tackle real social issues – which it is. Recreational drug use should not be encouraged, but the use of technology to help people should definitely be. If we can save the life of one person with this app then we have done our job.

Source link

]]> 0
State AG pushes accountability in opioid business Mon, 07 Jun 2021 15:31:49 +0000

Massachusetts Attorney General Maura Healey has been a leader in legal efforts to hold businesses and individuals accountable for the epidemic of opioid dependence and overdose in the United States, which has been linked to nearly 500,000 deaths over the past two decades.

Healey was the first of many state attorneys general to prosecute individual members of the Sackler family who own Connecticut-based Purdue Pharma, maker of OxyContin. She joined about half of state attorneys general in opposing the company’s proposed settlement in bankruptcy court. He calls for the disbandment of Purdue and its transformation into a new company that would use the proceeds from OxyContin sales to fight the crisis. Healey and others say it doesn’t go far enough.

Purdue and the Sacklers are defending the plan, saying it would take the business out of family hands and provide billions of dollars to deal with the opioid crisis. A U.S. bankruptcy court judge in New York this month allowed the company to begin asking creditors to vote on whether or not to approve the plan, which the company says is worth more than $ 10 billion. A hearing is scheduled for August.

Healey is scheduled to appear before a congressional committee on Tuesday to testify in favor of a bill that would clarify bankruptcy laws so that business owners and executives cannot use a business bankruptcy case to get themselves. protect from their personal liability. The legislation was inspired by the Purdue case.

Also this year, Healey became the first attorney general to sue a marketing firm, Publicis Health, claiming she had also played a role in the opioid epidemic through her work for Purdue. The company claims to have acted legally and that the lawsuit is without merit.

The Purdue bankruptcy is the most high-profile case in a complicated universe of opioid lawsuits across the United States that has drawn comparisons to the multi-state litigation against the tobacco companies of the 1990s. The Interview with Healey, which was held on June 3, was condensed.

AP: Purdue’s bankruptcy plan calls on members of the Sackler family to relinquish control of the company, with future profits being used to alleviate the opioid crisis, and to pay out nearly $ 4.3 billion over the course of the year. time. This is in addition to the more than $ 200 million they are paying in a federal settlement. Why do you think this offer is not enough to empower the company and its owners?

HEALEY: The Sacklers are not offering to pay anything near what they owe for the harm and devastation caused to families and communities across this country.

What it would do is pay a paltry total of less than $ 1.3 billion over the next five years to states, cities and counties. It’s far too little and far too late as they continue to sit on a fortune of at least $ 11 billion – a fortune built from sales of OxyContin and a fortune built at the expense of so many victims. across this country and devastation.

And the worst part is that they also went back to bankruptcy court with this proposal to basically buy immunity with a fraction of those returns. So, hey, this is their plan. They want to continue to be rich and they will probably be richer after paying the settlement than they are today. It doesn’t suit me and it shouldn’t suit anyone.

ÁP: The proposed settlement would give (members of the Sackler family) some immunity from civil lawsuits, but not from criminal charges. On what grounds, if any, could family members face criminal charges?

HEALEY: Nothing in the Civil Resolution will nullify or in any way eliminate the possibility of a criminal investigation or prosecution. I can tell you as a prosecutor that the government must make its case and that every individual has the right to a defense. But here’s a situation where we’ve sued Purdue and the Sacklers to get the money we desperately need to help our states, cities, and families.

AP: State attorneys general are almost equally divided on whether this is an acceptable deal. Why don’t you all agree on this?

HEALEY: When it comes to law enforcement, my job is to hold people accountable when they break the law, whether it’s rich and powerful corporations or rich and powerful people who seem to be in a position to buy the legal defense and team of lawyers they need to keep delaying and fighting this in court.

But for me, the responsibility is so important. It is important to the victims, survivors and families we serve and are elected to represent in our state. Accountability is important for fairness, for justice, for ensuring the safety of people and as a matter of deterrence to ensure that bad things like this do not happen again.

Purdue’s plan should require a public filing of every document in this case. We did it for tobacco; we should do it here. I strongly believe in it. The country deserves to know how Purdue and the Sacklers caused this opioid epidemic. We cannot continue to let them keep this a secret.

The Sackler plan wants the government to resume the drug trade, task us with selling OxyContin. Putting governments in a position to profit from the sale of OxyContin is simply perverse and grossly inappropriate. We don’t want it. Instead, we want a swift and orderly liquidation of this disgraced business.

AP: Earlier this year you filed complaints against Publicis. He’s a marketing consultant for Purdue. Why did you do this and do you expect lawsuits against other companies that work for the pharmaceutical industry?

HEALEY: During our investigation of Purdue and the Sacklers, we learned that Publicis was actively involved in consulting and providing marketing advice to Purdue and the Sacklers to help them increase sales of OxyContin. In doing so, they created a huge public nuisance. They have engaged in an unfair and deceptive violation of our consumer protection law.

There were a number of entities and perpetrators involved in this deadly and devastating opioid epidemic. And we’re going to continue to hold each of them accountable – or at least try to do so. We owe it to our families and we owe it in the name of justice.

AP: There are currently lawsuits involving claims against drugmakers in California and distribution companies in West Virginia. I wonder what the results of these cases will mean for all opioid litigation in the United States.

HEALEY: They benefit the public and the press because the facts are exposed. People must testify in public under oath. This is how accountability can be achieved.


Mulvihill reported from Cherry Hill, New Jersey.

Source link

]]> 0
Sangareddy youth celebrate their birthday with blood donation Sun, 06 Jun 2021 18:09:20 +0000

Akhil Goud Salapala has also asked 13 of his friends to donate blood in the past three months

Sangareddy: To make his birthday special, a 23-year-old and his two friends donated blood on Saturday to help thalassemia patients.

Akhil Goud Salapala donated blood for the first time in his life three months ago on the advice of his former math teacher Paisa Satyam working at ZPHS IDA Bollaram school. Since then, Akhil has encouraged 13 of his friends, including two on his birthday, to donate blood at various hospitals.

Speaking to Telangana Today, Akhil, who now works as a supervisor at a pharmaceutical company, said he received a call from his school teacher Satyam asking him to donate blood to someone. Until then, Akhil said he didn’t even know what his blood type was. Subsequently, the blood group was revealed to be A +, which matched the blood type of the person who was in the emergency at the time. He said he felt great after giving blood as a lifesaving gift.

“I have discovered that blood banks and hospitals are in dire need of blood because not many people show up to donate blood during the pandemic. To do my part, I have donated blood to 13 of my friends over the past three months, ”Akhil said. To make his birthday celebrations special, he said he went to the Thalassemia Sickle Cell Society in Rajendra Nagar in Hyderabad with his friends – Hemanth Ganesh and Kamesh, to donate blood.

Akhil Goud has pledged that he will continue to donate blood on every birthday in addition to encouraging his friends and family to embrace the humanitarian call for blood donation that will make the difference between life and death. He also planted a sapling on his birthday. His teacher Satyam appreciated his student for his determination.

Now you can get handpicked stories from Telangana today at Telegram everyday. Click on the link to subscribe.

Click to follow the Telangana Today Facebook page and Twitter .

Source link

]]> 0
Malta-based pharmaceutical company offers to supply 60 million doses of Sputnik V to Haryana, Health News, ET HealthWorld Sun, 06 Jun 2021 04:38:21 +0000

Chandigarh: The Haryana government informed on Saturday that it had received an “expression of interest” from a Malta-based pharmaceutical company to provide up to 60 million doses of Sputnik V Covid-19 vaccine.

It comes a day after the state government’s global tender for pharmaceutical companies to supply 1 crore of Covid-19 vaccines to the state expired on Friday.

“Although the offer arrived after the tender deadline, it is still carefully reviewed to see if it meets the criteria of the tender document and to ensure optimum availability. vaccine for the state, ”said Rajeev Arora, Additional Chief Secretary, Health, Haryana.

Haryana had launched a global tender through Haryana Medical Services Corporation (HMSCL) on May 26, which closed on June 4. Expression of interest in HMSCL to deliver up to 60 million doses Sputnik V vaccine, ”the Haryana government said.

The government added that the cost of each dose will be close to Rs 1,120. The company has given 30 days to deliver the first batch of five lakh doses of the vaccine, which will be followed by the supply of one million. doses every 20 days.

Source link

]]> 0
Global Calcineurin Inhibitors Market Future Forecast 2021 Report with Latest Industry Developments 2028 – The Manomet Current Fri, 04 Jun 2021 17:03:33 +0000

the Global Calcineurin Inhibitors Market The analysis report is generated in a way that makes the reports easier to read and makes it easier for managers to absorb the information they need to make decisions. Market insights are made more accessible to customers with the help of this report. This report includes actionable market research and is educational and entertaining as well. The varied and in-depth report helps companies gain a data-driven perspective on the topics shaping industries and geographies. This winning market paper very effectively gathers and analyzes data on customers, competitors, distributors and other market players and forces.

Global Calcineurin Inhibitors Market Research report uses graphics and tables to make it more visually interesting. This is the best way for users to understand the customer and thus increase their satisfaction by meeting needs and expectations. It also helps to see what factors are influencing the business, where the brand is located and to know the temperature of the market before a product is launched. Once all the analyzes and market studies have been carried out, it is time to present them effectively, in order to get everyone on board and make the right decisions for the business strategy, the market research reports are the key allies in the process. matter.

Market Analysis and Outlook: Global Calcineurin Inhibitors Market

The global calcineurin inhibitors market is expected to witness the market growth during the forecast period of 2020 to 2027. Data Bridge Market Research analyzes that the market grows at a healthy CAGR during the mentioned research forecast period above. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market.

Get Sample Report + All Related Charts and Charts @

Competitive Landscape and Global Calcineurin Inhibitors Market Share Analysis

Global Calcineurin Inhibitors Market competitive landscape provides details by competitor. details included are company presentation, company finances, revenue generated, market potential, investment in research and development, new market initiatives, global presence, locations and production facilities, company strengths and weaknesses, product launches, clinical trial pipelines, product approvals, patents, product width and breadth, application dominance, lifeline curve technological. the above data points provided are related only to the focus of the companies on the global Calcineurin Inhibitors market.

The major players in the global calcineurin inhibitors market are Astellas Pharma Inc, Leo Pharma A / S, Novartis AG, Mylan NV, Pfizer Inc, Dr. Reddy’s Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Veloxis Pharmaceuticals, Inc, Sun Pharmaceutical Industries, Inc., Wockhardt, Teva Pharmaceuticals Industries Inc, AbbVie Inc, Apotex Inc, Allergan, Amneal Pharmaceuticals Inc, Mayne Pharma Group Limited and others.

The global calcineurin inhibitor market is primarily driven by the high incidence of atopic dermatitis and psoriasis and the availability of a new formulation. Further, increasing patient awareness and improving healthcare facilities are some of the impact factors driving the growth of the market. Nevertheless, the expiration of the patents of the branded version and the side effects of the drugs leading to the discontinuation of the drugs are significantly hampering the growth of this market.

Calcineurin inhibitors are a class of immunosuppressive agents that work by inhibiting the action of an enzyme called calcineurin. This enzyme is responsible for activating T cells in the immune system which play an important role in cell-mediated immunity.

Global Calcineurin Inhibitors Market provides details on market share, new developments and product pipeline analysis, impact of domestic and localized market players, analysis for opportunities in terms of emerging revenue pockets , changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the market analysis and scenario, contact us for an analyst brief, our team will help you create a revenue impact solution to achieve the desired goal.

Grab your report with an impressive 30% discount! Please click here @

Global Calcineurin Inhibitors Market Scope and Size

The global calcineurin inhibitor market is segmented on the basis of disease, drug, route of administration, end users, and distribution channel.

  • The global calcineurin inhibitor market is segmented on the basis of disease into atopic dermatitis, postoperative immunosuppression, ulcerative colitis, psoriasis, keratoconjunctivitis, and others.
  • Based on the drug, the global calcineurin inhibitor market is segmented into cyclosporine, tacrolimus, pimecrolimus, and others.
  • The route of administration segment for the global calcineurin inhibitor market is segmented into oral, topical, and parenteral.
  • On the basis of end users, the global calcineurin inhibitor market is segmented into hospitals, homecare, specialty centers, and others.
  • On the basis of distribution channel, the global calcineurin inhibitor market has been divided into hospital pharmacy, online pharmacy, and retail pharmacy.

Global Calcineurin Inhibitors Market Analysis at Country Level

Global Calcineurin Inhibitors Market is analyzed and market size information provided by country, disease, drug, administration route end user and distribution channel as noted above.

Countries Covered in Global Calcineurin Inhibitors Market Report are United States, Canada, Mexico North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, UK, Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, Asia- region Pacific, United Arab Emirates, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as part of Middle East and Africa.

In terms of region, North America accounts for the largest market share throughout the forecast period owing to the high prevalence of atopic dermatitis and the presence of sophisticated healthcare infrastructure that can enable a effective treatment of patients with infections. Europe is a lucrative market due to the presence of key global and national players in this region and an increasing focus on research and development. Asia-Pacific and South America are expected to dominate the market due to the increasing population and the strong presence of the generic manufacturer.

For more information, get a detailed table of contents @https: // Dbmr = global-calcinerin-inhibitors-market

The country section of the report also provides the individual market impact factors and regulatory changes in the market at the national level which are impacting current and future market trends. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the main indicators used to forecast the market scenario for each country. . In addition, the presence and availability of global brands and their challenges due to significant or rare competition from local and national brands, the impact of sales channels are taken into account while providing forecast analysis of country data.

Epidemiological analysis of patients

The global calcineurin inhibitors market also provides you with detailed market analysis for patient analysis, prognosis, and treatment. Prevalence, incidence, mortality, adherence rates are some of the data variables available in the report. Analyzes of direct or indirect impact of epidemiology on market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market during the growth period.

About the Data Bridges Market Research:

Data Bridge Market Research has presented itself as an unconventional, neoteric market research and consulting company with an unprecedented level of resilience and integrated approaches. We are committed to finding the best market opportunities and promoting effective information for your business to thrive in the market. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process.


Market research on data bridges

United States: +1 888 387 2818

UK: +44 208 089 1725

Hong-Kong: +852 8192 7475

Source link

]]> 0